SI3260136T1 - Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa - Google Patents

Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa

Info

Publication number
SI3260136T1
SI3260136T1 SI201032049T SI201032049T SI3260136T1 SI 3260136 T1 SI3260136 T1 SI 3260136T1 SI 201032049 T SI201032049 T SI 201032049T SI 201032049 T SI201032049 T SI 201032049T SI 3260136 T1 SI3260136 T1 SI 3260136T1
Authority
SI
Slovenia
Prior art keywords
hiv
immunodeficiency virus
human immunodeficiency
neutralizing antibodies
neutralizing
Prior art date
Application number
SI201032049T
Other languages
English (en)
Inventor
Po-Ying Chan-Hui
Jennifer Mitcham
Ole Olsen
Steven Frey
Matthew Moyle
Sanjay K. Phogat
Dennis Burton
Laura Marjorie Walker
Pascal Raymond Georges Poignard
Melissa Danielle De Jean De St. Marcel Simek-Lemos
Wayne Koff
Stephen Kaminsky
Original Assignee
Theraclone Sciences, Inc.
The Scripps Research Institute
International Aids Vaccine Initiative
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraclone Sciences, Inc., The Scripps Research Institute, International Aids Vaccine Initiative filed Critical Theraclone Sciences, Inc.
Publication of SI3260136T1 publication Critical patent/SI3260136T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SI201032049T 2009-03-17 2010-03-01 Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa SI3260136T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16101009P 2009-03-17 2009-03-17
US16582909P 2009-04-01 2009-04-01
US22473909P 2009-07-10 2009-07-10
US28566409P 2009-12-11 2009-12-11
EP17173548.3A EP3260136B1 (en) 2009-03-17 2010-03-17 Human immunodeficiency virus (hiv) -neutralizing antibodies

Publications (1)

Publication Number Publication Date
SI3260136T1 true SI3260136T1 (sl) 2021-05-31

Family

ID=42668183

Family Applications (4)

Application Number Title Priority Date Filing Date
SI201032049T SI3260136T1 (sl) 2009-03-17 2010-03-01 Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
SI201032062T SI3323427T1 (sl) 2009-03-17 2010-03-17 Protitelesa, ki nevtralizirajo virus humane imunske pomanjkljivosti (HIV)
SI201031616T SI2408476T1 (sl) 2009-03-17 2010-03-17 Humani imunodificientni virus (hiv)-nevtralizirajoča protitelesa
SI201032112T SI3542817T1 (sl) 2009-03-17 2010-03-17 Virus humane imunske pomanjkljivosti(HIV) - nevtralizirajoča protitelesa

Family Applications After (3)

Application Number Title Priority Date Filing Date
SI201032062T SI3323427T1 (sl) 2009-03-17 2010-03-17 Protitelesa, ki nevtralizirajo virus humane imunske pomanjkljivosti (HIV)
SI201031616T SI2408476T1 (sl) 2009-03-17 2010-03-17 Humani imunodificientni virus (hiv)-nevtralizirajoča protitelesa
SI201032112T SI3542817T1 (sl) 2009-03-17 2010-03-17 Virus humane imunske pomanjkljivosti(HIV) - nevtralizirajoča protitelesa

Country Status (15)

Country Link
US (7) US9051362B2 (sl)
EP (5) EP2408476B1 (sl)
AU (5) AU2010226668B2 (sl)
CA (2) CA2755821C (sl)
CY (1) CY1121323T1 (sl)
DK (1) DK2408476T3 (sl)
ES (4) ES2916404T3 (sl)
HR (1) HRP20180027T1 (sl)
HU (1) HUE036031T2 (sl)
LT (1) LT2408476T (sl)
NO (1) NO2408476T3 (sl)
PL (4) PL3260136T3 (sl)
PT (4) PT3260136T (sl)
SI (4) SI3260136T1 (sl)
WO (1) WO2010107939A2 (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
US20110212106A1 (en) * 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
EP2542703A4 (en) * 2010-03-02 2013-10-23 Int Aids Vaccine Initiative NEW HIV-1 ENVELOPE GLYCOPROTEIN
EP3556396B1 (en) * 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2012040562A2 (en) 2010-09-24 2012-03-29 International Aids Vaccine Initiative Novel hiv-1 broadly neutralizing antibodies
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
WO2013006688A2 (en) 2011-07-05 2013-01-10 Duke University N-terminal deleted gp120 immunogens
US8791108B2 (en) * 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
WO2013052095A2 (en) 2011-10-03 2013-04-11 Duke University Vaccine
WO2013085550A2 (en) * 2011-12-05 2013-06-13 Duke University V1v2 immunogens
WO2013086533A1 (en) 2011-12-08 2013-06-13 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
WO2013142324A1 (en) * 2012-03-23 2013-09-26 Usa, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
EP2961427B1 (en) * 2013-02-28 2020-03-25 Gnvie, Llc Hiv antigens and antibodies
EP3010549A4 (en) * 2013-06-17 2017-03-15 Emory University Pathogen binding agents conjugated to radioisotopes and uses in imaging and therapeutic applications
WO2015048517A1 (en) * 2013-09-28 2015-04-02 Duke University Escape mutants
WO2015127108A1 (en) * 2014-02-19 2015-08-27 Duke University Trimeric hiv-1 envelopes compositions and uses thereof
US10093720B2 (en) * 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
BR112017000528A2 (pt) 2014-07-11 2017-11-14 Gilead Sciences Inc moduladores dos receptores toll-like para o tratamento do hiv
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
WO2016054053A2 (en) * 2014-09-29 2016-04-07 Duke University Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
BR112018005931A2 (pt) * 2015-09-24 2018-10-09 Abvitro Llc composições de anticorpo para hiv e métodos de uso
DK3390441T3 (da) 2015-12-15 2021-10-11 Gilead Sciences Inc Antistoffer til neutralisering af human immundefekt virus
CN107022027B (zh) * 2016-02-02 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
CN107033241B (zh) * 2016-02-03 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
WO2018237357A1 (en) * 2017-06-22 2018-12-27 University Of Maryland, Baltimore HIV-LARGE SPECTRUM HIV NEUTRALIZATION ANTIBODIES AGAINST HIV
PE20210685A1 (es) 2018-07-03 2021-04-08 Gilead Sciences Inc Anticuerpos que se dirigen al gp120 de vih y metodos de uso
WO2020082045A1 (en) * 2018-10-19 2020-04-23 University Of Maryland, College Park Multispecfic anti-hiv antibodies
AU2020315598A1 (en) 2019-07-16 2022-03-03 Gilead Sciences, Inc. HIV vaccines and methods of making and using
US20230134571A1 (en) * 2019-10-29 2023-05-04 International Aids Vaccine Initiative Engineered antibodies to hiv env
US20210277093A1 (en) * 2020-03-09 2021-09-09 Adma Biologics, Inc. Immunotherapeutic compositions and methods of production for coronavirus
IL300256A (en) 2020-08-25 2023-03-01 Gilead Sciences Inc Multispecific Antigen Binding Molecules Targeting HIV and Methods of Use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022162009A1 (en) 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022161597A1 (en) * 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022225875A1 (en) * 2021-04-19 2022-10-27 The Wistar Institute Of Anatomy And Biology Sialydase linked hiv antibodies and methods of use
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
KR0149181B1 (ko) 1990-06-29 1998-08-17 데이비드 알, 맥지 형질전환된 미생물에 의한 멜라닌의 제조방법
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0794792A1 (en) 1994-12-02 1997-09-17 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
WO2004063343A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
AU2005302416A1 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies
EP3556396B1 (en) * 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies

Also Published As

Publication number Publication date
ES2916404T3 (es) 2022-06-30
EP3260136B1 (en) 2020-11-25
US20190338017A1 (en) 2019-11-07
LT2408476T (lt) 2018-03-26
AU2017264985B2 (en) 2020-05-07
PL2408476T3 (pl) 2018-05-30
SI3323427T1 (sl) 2021-07-30
US20150218257A1 (en) 2015-08-06
EP3260136A1 (en) 2017-12-27
AU2020210242A1 (en) 2020-08-20
EP2408476B1 (en) 2017-10-18
PL3542817T3 (pl) 2022-09-19
US20230295278A1 (en) 2023-09-21
PT2408476T (pt) 2018-01-19
SI3542817T1 (sl) 2022-09-30
US9920111B2 (en) 2018-03-20
CA2980883C (en) 2020-12-29
CA2980883A1 (en) 2010-09-23
EP3323427B1 (en) 2021-01-13
HUE036031T2 (hu) 2018-06-28
EP3323427A1 (en) 2018-05-23
AU2010226668A1 (en) 2011-10-06
NO2408476T3 (sl) 2018-03-17
US11584789B2 (en) 2023-02-21
EP3542817B1 (en) 2022-05-11
CA2755821C (en) 2017-11-14
AU2010226668B2 (en) 2015-07-16
HRP20180027T1 (hr) 2018-04-20
CY1121323T1 (el) 2020-05-29
EP2408476A2 (en) 2012-01-25
US20190169273A1 (en) 2019-06-06
AU2023204017A1 (en) 2023-07-13
ES2848203T3 (es) 2021-08-05
PL3323427T3 (pl) 2021-10-11
US20110044994A1 (en) 2011-02-24
ES2656234T3 (es) 2018-02-26
PL3260136T3 (pl) 2021-10-18
EP3542817A1 (en) 2019-09-25
PT3323427T (pt) 2021-03-03
US20190031742A1 (en) 2019-01-31
PT3260136T (pt) 2021-02-12
WO2010107939A3 (en) 2011-05-26
US10865234B2 (en) 2020-12-15
ES2848555T3 (es) 2021-08-10
US10239934B2 (en) 2019-03-26
AU2017264985A1 (en) 2017-12-07
US10407493B2 (en) 2019-09-10
AU2015234345B2 (en) 2017-09-21
EP4085925A1 (en) 2022-11-09
AU2020210242B2 (en) 2023-04-06
SI2408476T1 (sl) 2018-04-30
US9051362B2 (en) 2015-06-09
AU2015234345C1 (en) 2017-12-21
WO2010107939A2 (en) 2010-09-23
DK2408476T3 (en) 2018-01-22
PT3542817T (pt) 2022-07-05
AU2015234345A1 (en) 2015-11-05
US20210040186A1 (en) 2021-02-11
CA2755821A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
PT2408476T (pt) Anticorpos de neutralização do vírus de imunodeficiência humana (hiv)
AU2016202543A1 (en) Human immunodeficiency virus (hiv)-neutralizing antibodies
EP2611465A4 (en) NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV)
HK1212935A1 (zh) 廣譜中和抗 抗體
AP2011005944A0 (en) Inhibitors of human immunodeficiency virus replication.
EP2380976A4 (en) HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
PT3494972T (pt) Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
DK3329772T3 (da) Dobbeltvektor til inhibering af human immundefektvirus
ZA201202116B (en) Neutralizing antibodies to hiv-1 and their use
EP2618843A4 (en) NEW ANTIBODIES WITH EXCESSIVE HIV-1 NEUTRALIZATION
EP2542703A4 (en) NEW HIV-1 ENVELOPE GLYCOPROTEIN
IL222228A0 (en) Hiv vaccine
ZA201002445B (en) Hiv preventive vaccine based on hiv specific antibodies
IL212311A0 (en) Immunoenhancer-linked oligomeric hiv vaccines
EP2571523A4 (en) REACTIVATION OF THE HUMAN IMMUNODEFICIENCY VIRUS IN THE LATENT STATE
AP2013007180A0 (en) Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
EP2635300A4 (en) DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
GB0912950D0 (en) Virus
EP2542252A4 (en) HIV-1 CASE-BASED FRAGMENTS
ZA201302639B (en) Antibodies for the treatment of hiv
EP2643460A4 (en) METHOD, COMPOSITIONS AND KITS FOR IDENTIFYING HUMAN IMMUNE FIZIENZVIRUS (HIV)
ZA201105357B (en) Splitting gp41
GB0901056D0 (en) Virus
HK1177692A1 (zh) 新的流感病毒
ZA201105396B (en) Novel gp41 antigens